Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Strong Trading Volume – What’s Next?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw unusually-strong trading volume on Thursday . Approximately 301,653 shares were traded during trading, an increase of 43% from the previous session’s volume of 211,270 shares.The stock last traded at $26.61 and had previously closed at $24.91.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on CHGCY shares. UBS Group upgraded shares of Chugai Pharmaceutical to a “strong-buy” rating in a research note on Tuesday, January 27th. Smbc Nikko Sec. upgraded shares of Chugai Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, According to MarketBeat.com, Chugai Pharmaceutical presently has a consensus rating of “Strong Buy”.

Chugai Pharmaceutical Stock Down 4.1%

The firm has a market capitalization of $86.70 billion, a price-to-earnings ratio of 29.27 and a beta of 0.63. The stock has a 50-day moving average price of $28.49 and a 200 day moving average price of $27.06.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its quarterly earnings data on Friday, April 24th. The company reported $0.22 EPS for the quarter. Chugai Pharmaceutical had a return on equity of 22.40% and a net margin of 34.98%.The business had revenue of $2.05 billion during the quarter.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.